No quarterly revenue total was found in Achieve Life Sciences, Inc.'s SEC filings.
Achieve Life Sciences, Inc. (ACHV) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. Free cash flow was -$10.8 million. As of Jun 30, 2026 it held $187.3 million in cash and investments and $36,000 in total debt.
Revenue
—
Net income
$-74.77M
-487.9% vs year-ago quarter
Operating cash flow
$-10.78M
-18.8% vs year-ago quarter
Free cash flow
$-10.79M
EPS
$-0.80
-116.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
102.90M
+101.4% vs year-ago quarter
Net cash
$187.27M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- ACHV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 949858
- Former names
- ONCOGENEX PHARMACEUTICALS, INC. (until Jul 31, 2017); SONUS PHARMACEUTICALS INC (until Aug 7, 2008)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Net income | -$74.8M | -$10.2M | -$14.7M | -$14.4M | -$12.7M |
| Diluted EPS | -$0.80 | -$0.19 | -$0.27 | -$0.28 | -$0.37 |
| Operating cash flow | -$10.8M | -$6.9M | -$18.0M | -$11.3M | -$9.1M |
| Free cash flow | -$10.8M | — | — | — | — |
| Total assets | $190.4M | $33.1M | $41.8M | $52.0M | $58.9M |
| Total liabilities | $205.1M | $22.4M | $20.3M | $18.4M | $17.3M |
| Stockholders' equity | -$14.7M | $10.7M | $21.5M | $33.6M | $41.7M |
| Cash and investments | $187.3M | $29.3M | $36.4M | $48.1M | $55.4M |
| Total debt | $36,000 | $51,000 | $66,000 | $80,000 | $95,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jul 6, 2026 | Jul 2, 2026 |
| ARS | Annual report to shareholders | Jun 8, 2026 | Dec 31, 2025 |
All 1000 Achieve Life Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.